Health
Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI – Insight – BioSpace
Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic…
Series of preclinical studies demonstrate the therapeutic potential of PAT-DX1, a first-in-class, synthetically lethal DNA-binding antibody in primary brain cancers and brain metastases.MELBOURNE–(BUSINESS WIRE)– Patrys Limited (ASX:PAB), a therapeutic…
Continue Reading